Insulin sensitizers may attenuate lean mass loss in older men with diabetes

Christine G. Lee, Edward J. Boyko, Elizabeth Barrett-Connor, Iva Miljkovic, Andrew R. Hoffman, Susan Everson-Rose, Cora E. Lewis, Peggy Mannen Cawthon, Elsa S. Strotmeyer, Eric S. Orwoll

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

OBJECTIVE - To examine longitudinal changes in total and appendicular lean body mass in older men with impaired fasting glucose (IFG) or diabetes and to determine whether these changes differ by diabetes treatment. RESEARCH DESIGN AND METHODS - A total of 3,752 ambulatory men aged ≥65 years at baseline participated in amulticenter longitudinal cohort study. Baseline glycemic status was categorized as normoglycemia, IFG, undiagnosed/untreated diabetes, or treated diabetes. Insulin sensitizer medication use (metformin and/or thiazolidinediones) was assessed by prescriptionmedication inventory. The change in total lean and appendicular lean mass was derived from dual X-ray absorptiometry scans taken at baseline and 3.5 ± 0.7 years later. RESULTS - This male cohort included 1,853 individuals with normoglycemia, 1,403 with IFG, 234 with untreated diabetes, 151 with diabetes treatedwith insulin sensitizers, and 111 with diabetes treated without insulin sensitizers. Men with untreated diabetes, diabetes treated without insulin sensitizers, or IFG had greater percentage loss in total or appendicular lean mass (P≤ 0.05 in comparison to normoglycemic men). There remained a significantly greater percentage loss in appendicular lean mass for these groups even after adjustment for medical comorbidities or lifestyle factors. In contrast, the percentage loss in total or appendicular lean mass in men with diabetes treated with insulin sensitizers was significantly less than that in normoglycemic men in minimally and fully adjusted models. CONCLUSIONS - Skeletal muscle loss was accelerated inmen with IFG and diabetes, except when the latter was treated with insulin sensitizers. These findings suggest that insulin sensitizers may attenuate muscle loss.

Original languageEnglish (US)
Pages (from-to)2381-2386
Number of pages6
JournalDiabetes care
Volume34
Issue number11
DOIs
StatePublished - Nov 1 2011

Fingerprint

Insulin
Fasting
Glucose
Thiazolidinediones
Metformin
Photon Absorptiometry
Longitudinal Studies
Life Style
Comorbidity
Skeletal Muscle
Cohort Studies
Research Design
Equipment and Supplies
Muscles
Therapeutics

Cite this

Lee, C. G., Boyko, E. J., Barrett-Connor, E., Miljkovic, I., Hoffman, A. R., Everson-Rose, S., ... Orwoll, E. S. (2011). Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes care, 34(11), 2381-2386. https://doi.org/10.2337/dc11-1032

Insulin sensitizers may attenuate lean mass loss in older men with diabetes. / Lee, Christine G.; Boyko, Edward J.; Barrett-Connor, Elizabeth; Miljkovic, Iva; Hoffman, Andrew R.; Everson-Rose, Susan; Lewis, Cora E.; Cawthon, Peggy Mannen; Strotmeyer, Elsa S.; Orwoll, Eric S.

In: Diabetes care, Vol. 34, No. 11, 01.11.2011, p. 2381-2386.

Research output: Contribution to journalArticle

Lee, CG, Boyko, EJ, Barrett-Connor, E, Miljkovic, I, Hoffman, AR, Everson-Rose, S, Lewis, CE, Cawthon, PM, Strotmeyer, ES & Orwoll, ES 2011, 'Insulin sensitizers may attenuate lean mass loss in older men with diabetes', Diabetes care, vol. 34, no. 11, pp. 2381-2386. https://doi.org/10.2337/dc11-1032
Lee CG, Boyko EJ, Barrett-Connor E, Miljkovic I, Hoffman AR, Everson-Rose S et al. Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes care. 2011 Nov 1;34(11):2381-2386. https://doi.org/10.2337/dc11-1032
Lee, Christine G. ; Boyko, Edward J. ; Barrett-Connor, Elizabeth ; Miljkovic, Iva ; Hoffman, Andrew R. ; Everson-Rose, Susan ; Lewis, Cora E. ; Cawthon, Peggy Mannen ; Strotmeyer, Elsa S. ; Orwoll, Eric S. / Insulin sensitizers may attenuate lean mass loss in older men with diabetes. In: Diabetes care. 2011 ; Vol. 34, No. 11. pp. 2381-2386.
@article{3232f735662045448243fc78de39ffac,
title = "Insulin sensitizers may attenuate lean mass loss in older men with diabetes",
abstract = "OBJECTIVE - To examine longitudinal changes in total and appendicular lean body mass in older men with impaired fasting glucose (IFG) or diabetes and to determine whether these changes differ by diabetes treatment. RESEARCH DESIGN AND METHODS - A total of 3,752 ambulatory men aged ≥65 years at baseline participated in amulticenter longitudinal cohort study. Baseline glycemic status was categorized as normoglycemia, IFG, undiagnosed/untreated diabetes, or treated diabetes. Insulin sensitizer medication use (metformin and/or thiazolidinediones) was assessed by prescriptionmedication inventory. The change in total lean and appendicular lean mass was derived from dual X-ray absorptiometry scans taken at baseline and 3.5 ± 0.7 years later. RESULTS - This male cohort included 1,853 individuals with normoglycemia, 1,403 with IFG, 234 with untreated diabetes, 151 with diabetes treatedwith insulin sensitizers, and 111 with diabetes treated without insulin sensitizers. Men with untreated diabetes, diabetes treated without insulin sensitizers, or IFG had greater percentage loss in total or appendicular lean mass (P≤ 0.05 in comparison to normoglycemic men). There remained a significantly greater percentage loss in appendicular lean mass for these groups even after adjustment for medical comorbidities or lifestyle factors. In contrast, the percentage loss in total or appendicular lean mass in men with diabetes treated with insulin sensitizers was significantly less than that in normoglycemic men in minimally and fully adjusted models. CONCLUSIONS - Skeletal muscle loss was accelerated inmen with IFG and diabetes, except when the latter was treated with insulin sensitizers. These findings suggest that insulin sensitizers may attenuate muscle loss.",
author = "Lee, {Christine G.} and Boyko, {Edward J.} and Elizabeth Barrett-Connor and Iva Miljkovic and Hoffman, {Andrew R.} and Susan Everson-Rose and Lewis, {Cora E.} and Cawthon, {Peggy Mannen} and Strotmeyer, {Elsa S.} and Orwoll, {Eric S.}",
year = "2011",
month = "11",
day = "1",
doi = "10.2337/dc11-1032",
language = "English (US)",
volume = "34",
pages = "2381--2386",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "11",

}

TY - JOUR

T1 - Insulin sensitizers may attenuate lean mass loss in older men with diabetes

AU - Lee, Christine G.

AU - Boyko, Edward J.

AU - Barrett-Connor, Elizabeth

AU - Miljkovic, Iva

AU - Hoffman, Andrew R.

AU - Everson-Rose, Susan

AU - Lewis, Cora E.

AU - Cawthon, Peggy Mannen

AU - Strotmeyer, Elsa S.

AU - Orwoll, Eric S.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - OBJECTIVE - To examine longitudinal changes in total and appendicular lean body mass in older men with impaired fasting glucose (IFG) or diabetes and to determine whether these changes differ by diabetes treatment. RESEARCH DESIGN AND METHODS - A total of 3,752 ambulatory men aged ≥65 years at baseline participated in amulticenter longitudinal cohort study. Baseline glycemic status was categorized as normoglycemia, IFG, undiagnosed/untreated diabetes, or treated diabetes. Insulin sensitizer medication use (metformin and/or thiazolidinediones) was assessed by prescriptionmedication inventory. The change in total lean and appendicular lean mass was derived from dual X-ray absorptiometry scans taken at baseline and 3.5 ± 0.7 years later. RESULTS - This male cohort included 1,853 individuals with normoglycemia, 1,403 with IFG, 234 with untreated diabetes, 151 with diabetes treatedwith insulin sensitizers, and 111 with diabetes treated without insulin sensitizers. Men with untreated diabetes, diabetes treated without insulin sensitizers, or IFG had greater percentage loss in total or appendicular lean mass (P≤ 0.05 in comparison to normoglycemic men). There remained a significantly greater percentage loss in appendicular lean mass for these groups even after adjustment for medical comorbidities or lifestyle factors. In contrast, the percentage loss in total or appendicular lean mass in men with diabetes treated with insulin sensitizers was significantly less than that in normoglycemic men in minimally and fully adjusted models. CONCLUSIONS - Skeletal muscle loss was accelerated inmen with IFG and diabetes, except when the latter was treated with insulin sensitizers. These findings suggest that insulin sensitizers may attenuate muscle loss.

AB - OBJECTIVE - To examine longitudinal changes in total and appendicular lean body mass in older men with impaired fasting glucose (IFG) or diabetes and to determine whether these changes differ by diabetes treatment. RESEARCH DESIGN AND METHODS - A total of 3,752 ambulatory men aged ≥65 years at baseline participated in amulticenter longitudinal cohort study. Baseline glycemic status was categorized as normoglycemia, IFG, undiagnosed/untreated diabetes, or treated diabetes. Insulin sensitizer medication use (metformin and/or thiazolidinediones) was assessed by prescriptionmedication inventory. The change in total lean and appendicular lean mass was derived from dual X-ray absorptiometry scans taken at baseline and 3.5 ± 0.7 years later. RESULTS - This male cohort included 1,853 individuals with normoglycemia, 1,403 with IFG, 234 with untreated diabetes, 151 with diabetes treatedwith insulin sensitizers, and 111 with diabetes treated without insulin sensitizers. Men with untreated diabetes, diabetes treated without insulin sensitizers, or IFG had greater percentage loss in total or appendicular lean mass (P≤ 0.05 in comparison to normoglycemic men). There remained a significantly greater percentage loss in appendicular lean mass for these groups even after adjustment for medical comorbidities or lifestyle factors. In contrast, the percentage loss in total or appendicular lean mass in men with diabetes treated with insulin sensitizers was significantly less than that in normoglycemic men in minimally and fully adjusted models. CONCLUSIONS - Skeletal muscle loss was accelerated inmen with IFG and diabetes, except when the latter was treated with insulin sensitizers. These findings suggest that insulin sensitizers may attenuate muscle loss.

UR - http://www.scopus.com/inward/record.url?scp=84863453315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863453315&partnerID=8YFLogxK

U2 - 10.2337/dc11-1032

DO - 10.2337/dc11-1032

M3 - Article

VL - 34

SP - 2381

EP - 2386

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 11

ER -